CompletedPhase 2

Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

Belgium, Netherlands30 participantsStarted 2014-10

Plain-language summary

The primary objective of this trial is as follows: To determine the pharmacokinetics of micafungin given twice weekly in patients at risk for developing an invasive fungal disease (patients who are being treated for acute or chronic graft versus host disease; patients receiving reduced intensity conditioning for Stem Cell Transplant (SCT); receiving first remission induction chemotherapy for Acute Myeloid Leucaemia (AML)/MyeloDysplasticSyndrome (MDS)) compared to the pharmacokinetics of micafungin given daily. The secondary objective of this trial is as follows: To determine whether adequate exposure of micafungin is attained. To determine the safety of micafungin in this patient population

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient receives immunosuppressive therapy for acute GvHD grade II-IV or reduced intensity conditioning regimens for allogeneic stem cell transplant, or patients receiving first remission induction chemotherapy for AML/MDS. * Subject is at least 18 of age on the day of providing informed consent. * Has no signs or symptoms of invasive fungal disease * If a woman, is neither pregnant nor able to become pregnant and is not nursing an infant. * Less than 1 week of immunosuppressive therapy for grade II-IV acute GvHD. * Is managed with a central venous catheter (preferably a quadruple Arrow-Howes™ Quad-Lumen 8.5,5 French; Arrow International). * Subject is able and willing to sign the Informed Consent before screening evaluations. Exclusion Criteria: * Documented history of sensitivity to medicinal products or excipients similar to those found in the micafungin preparation. * History of or current abuse of drugs, alcohol or solvents. * Inability to understand the nature of the trial and the procedures required. * Has not previously participated in this trial.

What they're measuring

area under the curve

Timeframe: day 4 and day 8

Trial details

NCT IDNCT02172768

SponsorRadboud University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-06